Global Anti Arrhythmic Drugs Market, By Drug class (Beta Blockers, Calcium Chain Blockers, sodium channel blockers, potassium channel blockers), Drugs (Amiodarone, Flecainide, Ibutilide, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Anti Arrhythmic Drugs Market Analysis and Size
The global anti arrhythmic drugs market is expected to witness huge growth in the forecast period. On an average, the rate of maintaining sinus rhythm is nearly closer to 30% to 50% at one year for the other tested anti arrhythmic drugs. The COVID-19 pandemic has restated the importance of maintaining heart health as patients suffering from heart-related comorbidities have been found to be at major risk of contracting the coronavirus. These drugs must be taken regularly for one to three weeks before a response is witnessed and for numerous months before the full effect occurs.
Data Bridge Market Research analyses a growth rate in the global anti arrhythmic drugs market in the forecast period 2022-2029. The expected CAGR of global anti arrhythmic drugs market is tend to be around 5.50% in the mentioned forecast period. The market was valued at USD 1.04 billion in 2021, and it would grow upto USD 1.60 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Anti-arrhythmic drugs are the type of therapeutics that belongs to the class of cardiovascular agents which are widely used in the management of patients suffering from cardiac arrhythmias. It exerts their action by controlling abnormal cardiac rhythm resulting from irregular electrical conductivity of the heart. Most arrhythmia medications are taken by mouth during a long period of time for lasting treatment. Some are taken intravenously for patients who are unstable or are not suitable for oral medications.
Anti Arrhythmic Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug class (Beta Blockers, Calcium Chain Blockers, sodium channel blockers, potassium channel blockers), Drugs (Amiodarone, Flecainide, Ibutilide, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd (Switzerland), Fresenius Kabi AG (Germany), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd (India), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Pfizer Inc (U.S.), Lupin (India), GSK Plc (U.K.), Glenmark Pharmaceuticals Inc (India), Amneal Pharmaceuticals (U.S.), Wockhardt (India)
|
|
Market Opportunities
|
|
Global Anti Arrhythmic Drugs Market Dynamics
Drivers
- Increase in Cardiovascular Diseases
According to the WHO, around 60% - 85% of population have adopted a sedentary life. According to CDC, approximately 31 million adults aged over 50 years lives a sedentary life, and only 1 out of 4 U.S. adults meets the appropriate need of physical activity. As a result, arrhythmic drugs are used widely to prevent this. This boost the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Increasing Adoption of Arrhythmic Drugs in ICU
As per the reports of NCBI, atrial fibrillation is observed in around 30% of medical intensive care units(MICU) patients. Many serious issues were observed in critically ill patients. Thus, in this regard, arrhythmic drugs are of great help to treat these patients. Thus, it creates more opportunity for the market growth.
- Increase in Elderly Population
The expansion of the atrial fibrillation market is prompted by rise in the frequency of atrial fibrillation in the elderly population, technical developments, and a preference for catheter ablation for cardiac arrhythmia therapy. Thus, it is helpful in driving the market growth.
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified personnel who are unable to treat the patients with these drugs could curb the growth of the global anti arrhythmic drugs market over a forecast period.
- Side Effects of arrhythmic drugs
There are various side-effects associated with the arrhythmic drugs that surely hamper the market growth. Effects such as dizziness, nausea, cardiovascular toxicity, gastrointestinal symptoms, immune-medicated reactions and many more are restricting the growth of the market.
This global anti arrhythmic drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global anti arrhythmic drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Anti Arrhythmic Drugs Market
The COVID-19 pandemic has significantly impacted the global anti arrhythmic drugs market. Several reports stated that around 16.7% of the hospitalized patients and 44.4% of patients in intensive care units (ICUs) had cardiac arrhythmia. Another study by Perelman School of Medicine at the University of Pennsylvania in July 2020 showed that the onset of the COVID-19 infection was associated with an increasing incidence of cardiac arrhythmias in patients.
The infection, in many cases, has deteriorated the pre-existing conditions, causing higher mortality rates among patients with chronic heart diseases. The coronavirus has, thus, intensified the adoption of critical care anti- arrhythmic drugs worldwide.
Global Anti Arrhythmic Drugs Market Scope
The global anti arrhythmic drugs market is segmented on the basis of drugs, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug class
- Beta Blockers
- Calcium Chain Blockers,
- Sodium channel blockers
- Potassium channel blockers
Drugs
- Amiodarone
- Flecainide
- Ibutilide
- Others
Route of Administration
- Oral
- Parenteral
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Anti Arrhythmic Drugs Market Regional Analysis/Insights
The global anti arrhythmic drugs market is analysed and market size insights and trends are provided by drugs, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global anti arrhythmic drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for global anti arrhythmic drugs market throughout the forecasted period due to the increase prevalence of cardiovascular complications and advanced healthcare facilities.
Asia-Pacific dominates the market due to the increase’s cases of cardiovascular diseases and rapidly aging population.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Anti Arrhythmic Drugs Market Share Analysis
The global anti arrhythmic drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global anti arrhythmic drugs market.
Key players operating in the global anti arrhythmic drugs market include:
- F. Hoffmann-La Roche Ltd (Switzerland)
- Fresenius Kabi AG (Germany)
- Bayer AG (Germany)
- Sun Pharmaceutical Industries Ltd (India)
- Novartis AG (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd (Israel)
- Pfizer Inc (U.S.)
- Lupin (India)
- GSK Plc (U.K.)
- Glenmark Pharmaceuticals Inc (India)
- Amneal Pharmaceuticals (U.S.)
- Wockhardt (India)
SKU-